Zai Lab Limited
NASDAQ:ZLABBiotechnology
+$0.61 today
- Market cap
- $2.49B
- Beta
- 0.78
- P/E (TTM)
- -11.4
- EPS (TTM)
- -$0.16
Volume 1.04M
Average 0.87M
ZLAB Accumulated OCI
Accumulated other comprehensive income: unrealized gains and losses, such as currency translation, recorded outside net income.
Zai Lab LimitedNASDAQ: ZLAB
Accumulated OCI · Q2 FY2026 · quarter ended Jun 2026
Accumulated OCI falls 99.5% from a year ago
Accumulated OCI stood at $214K at the end of Q2 FY2026, down 99.5% from a year earlier and down 98.6% from the prior quarter. Over 3 fiscal years it compounded at +5.0% a year.
Context
- Accumulated OCI amounted to 0.0% of total assets at the end of Q2 FY2026, down 4.0 pp from a year earlier.
- Accumulated OCI increased in 2 of the last 3 fiscal years.
What to watch
Whether Accumulated OCI keeps falling in the next quarterly balance sheet after a -99.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Accumulated OCI history
USD · from the balance sheet
- Latest · FY2025
- 29.7M USD
- Year-over-year change
- -41.2%
| Period | Period end | Accumulated OCI | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 29.7M | -41.2% |
| FY2024 | 2024-12-31 | 50.52M | +34.3% |
| FY2023 | 2023-12-31 | 37.63M | +46.5% |
| FY2022 | 2022-12-31 | 25.69M | +208.6% |
| FY2021 | 2021-12-31 | (23.65M) | — |
Accumulated OCI vs competitors
How ZLAB compares with its peers on the latest reported figures
- Peers report in different currencies, so Accumulated OCI is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -99.5% is the lowest of 4, against a peer median of +60.9%.
- Accumulated OCI amounts to 0.0% of total assets for ZLAB, versus a peer median of 12.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
AAPGAscentage Pharma Group International | Dec 2025 | CN¥1.33B CNY | +360.1% | — | 33.5% |
| Jun 2026 | $214K USD | -99.5% | +5.0% | 0.0% | |
| Dec 2025 | -$4.35M USD | +4.2% | +21.9% | 12.6% | |
| Dec 2025 | -$4.53M USD | +60.9% | — | 0.3% | |
| Peer median (excluding ZLAB) | — | +60.9% | +21.9% | 12.6% | |
Competitors are the stored peer set for ZLAB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 964.1M | 1.01B | 790.15M | 449.67M | 679.57M |
| Short-term Investments | 445M | 0 | 16.3M | 330M | 10M |
| Net Receivables | 54.81M | 48.57M | 65.33M | 89.41M | 106.12M |
| Inventory | 18.95M | 31.62M | 44.83M | 39.88M | 74.75M |
| Other Current Assets | 0 | 35.67M | 23M | 141.53M | 148.85M |
| Total Current Assets | 1.5B | 1.12B | 939.61M | 1.05B | 1.02B |
| Property, Plant & Equipment (Net) | 58.28M | 78.77M | 68.69M | 69.48M | 66.54M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 9.66M | 8.4M | 16.46M | 58.93M | 76.14M |
| Long-term Investments | 15.61M | 6.43M | 9.22M | 3.12M | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 3.39M |
| Other Non-current Assets | 25.53M | 2.2M | 2.32M | 3.75M | 7.02M |
| Total Non-current Assets | 109.08M | 95.8M | 96.69M | 135.27M | 153.1M |
| Total Assets | 1.61B | 1.22B | 1.04B | 1.19B | 1.17B |
| Account Payables | 126.16M | 65.97M | 112.99M | 100.91M | 141.61M |
| Short-term Debt | 0 | 0 | 0 | 131.71M | 204.53M |
| Tax Payables | 8.82M | 13.28M | 16.99M | 5.15M | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 4.42M | 4.05M | 5.35M | 6.35M | 7.07M |
| Total Current Liabilities | 192.9M | 139.84M | 203.07M | 299.39M | 416.17M |
| Long-term Debt | 0 | 0 | 0 | 0 | 13.39M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 27.49M | 21.36M | 28.74M | 31.43M | 0 |
| Other Non-current Liabilities | 0 | 0 | 325K | 325K | 27.33M |
| Total Non-current Liabilities | 37.1M | 34.7M | 37.11M | 45.47M | 40.72M |
| Total Liabilities | 230M | 174.55M | 240.18M | 344.86M | 456.88M |
| Common Stock | 6K | 6K | 6K | 7K | 7K |
| Retained Earnings | (1.42B) | (1.86B) | (2.2B) | (2.45B) | (2.63B) |
| Accumulated OCI | (23.65M) | 25.69M | 37.63M | 50.52M | 29.7M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 1.38B | 1.05B | 796.12M | 840.9M | 715.5M |
| Total Debt | 15.54M | 20.39M | 15.15M | 153.47M | 224.26M |
| Net Debt | (948.56M) | (988.08M) | (775M) | (296.2M) | (455.31M) |
Zai Lab Limited
NASDAQ:ZLAB
Intrinsic Alpha fair value
Locked
Current Price
$22.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.